EP-1241: SBRT for localised prostate cancer: an evaluation of toxicity with frequent prospective assessment  by Henderson, D. et al.
S672                                                                                                                                         3rd ESTRO Forum 2015 
 
survival and overall survival were estimated using the Kaplan-
Meier method. 
Results: Median age was 85 years (range 68-97 years). There 
were 31 males and 24 females. Four deaths occurred during 
radiotherapy unrelated to treatment (3 from pneumonia and 
1 from urinary sepsis).  
Genito-urinary grade 2 and grade 3 acute toxicity was seen in 
20% and 10% respectively. Gastro-intestinal grade 2 and grade 
3 acute toxicity was seen in 9.5 % and <1% respectively. No 
grade 4 genito-urinary or gastro-intestinal toxicity was seen. 
16% reported other grade 2 acute toxicity and <1% reported 
other grade 3 acute toxicity.  
Grade 2 late toxicity (any) at 6 and 12 months was seen in 
19% and 10.5% respectively. Any grade 3 late toxicity at 6 and 
12 months was seen 6.5% and 5% respectively. 
Local control at 3 months following radiotherapy was 88% 
(95%CI 64%-99%). Local progression free survival at 1 year was 
88% (95%CI 77%-100%) and overall survival at 1 year was 64% 
(95% CI 50%-77%).  
Conclusions: Hypofractionated radiotherapy delivered with a 
plan of the day IGART approach offers good local control with 
acceptable toxicity in a patient population not suitable for 
radical bladder treatment. This strategy is now being 
evaluated in a randomised multi-centre trial (HYBRID study; 
hypofractionated bladder radiotherapy with or without image 
guided adaptive planning).  
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) is 
used increasingly for the treatment of localised prostate 
cancer (LPC). Although there is a significant body of data on 
efficacy, few published studies have assessed toxicity more 
than once during the first 12 weeks after treatment, 
potentially underestimating acute toxicity. This information 
is essential for informed patient consent. We aimed to 
accurately define the toxicity profile by prospective two-
weekly assessment. 
Materials and Methods: Patients were treated using the 
Cyberknife® system with a dose of 36.25Gy / 5# (PTV V36.25 
Gy > 95%; prostate V40 Gy > 95%). Patients were treated on 
alternate or consecutive week days (range: 5-12 days). No 
patients received hormonal therapy. IPSS and RTOG toxicity 
was prospectively assessed at 2, 4, 6, 8, 10 and 12 weeks 
from start of treatment. Thereafter, patients were assessed 
every 3 months for the first 2 years, then 6 monthly. This 
study was given prospective approval by our institutional 
Clinical Research Committee. 
Results: Forty consecutive patients were treated; 5 low, 34 
intermediate, and 1 high NCCN risk. Median follow up was 21 
months (range: 3-38). Median IPSS score at baseline was 6 
(IQR: 4-11). Peak median IPSS score was recorded at two 
weeks (17; IQR: 8-22), returning to baseline by 4-6 weeks. 
The incidence of acute grade 2+ RTOG GU and GI toxicity was 
25% (10) and 20% (8), respectively, peaking at 2-3 weeks. 
Forty eight percent (19) received an α-blocker, either 
prophylactically (13%, 5 patients) or for urinary symptoms. 
One case of grade 3 GU toxicity occurred at 8 weeks due to 
mild transient haematuria. A single case of grade 3 GI 
toxicity occurred at 4 weeks due to a small amount of faecal 
incontinence. All acute toxicity had settled to grade 0-1 by 
week 10. No difference in acute toxicity was observed 
between patients having daily or alternate daily treatment. 
Incidence of late grade 2+ toxicity was 5% (2) for GU domain 
and 5% (2) for GI domain. Median PSA at baseline, 12 months 
and 24 months was 9, 0.96 and 0.65, respectively. 
Conclusions: Acute toxicity from SBRT for LPC peaks earlier 
than that of conventionally fractionated radiotherapy, but 
resolved rapidly and completely. Infrequent assessment risks 
underestimation of toxicity in this emerging treatment. SBRT 
should be evaluated in randomised trials, such as the PACE 
study, against current standards of care. 
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Purpose/Objective: Clinical data suggest that large radiation 
fractions are biologically superior to smaller fraction sizes in 
prostate cancer radiotherapy. Hypofractionated prostate 
stereotactic body radiotherapy aims to minimize the dose to 
the surrounding critical normal structures while delivering a 
large dose to the target volume. The CyberKnife is an 
appealing delivery system for hypofractionated radiosurgery 
due to its ability to deliver highly conformal radiation and to 
track and adjust for prostate motion in real-time. We 
compared outcomes in intermediate to high risk prostate 
cancer patients treated with cyberknife for boost after 
internsity modulated radiation therapy (IMRT) or three-
dimensional conformal radiation therapy (3-DRT).  
Materials and Methods: This study was based on a 
retrospective chart review analysis of the 46 patients treated 
with CyberKnife radiotherapy for localized prostate cancer. 
27 patients treated with 3DRT to a dose of 45 Gy in 25 
fractions and 19 patients with IMRT to same dose and all 
patients received a boost by the CyberKnife at dose of 21 Gy 
in 3 fractions. The acute toxicities were recorded using the 
RTOG acute toxicity scale and the Common Terminology 
Criteria for Adverse Events, version 3.0.  
Results: All 46 patients finished planed radiation therapy 
without any severe complication. The median follow-up for 
patients was 38 months (range 6 - 56 months). There were 
two biochemical failures in high risk patients in 3-DRT+CK 
and one in IMRT+CK group. The 3-year actuarial biochemical 
progression-free survival was 92.3% for 3-DRT+CK and 94.8% 
for IMRT+CK (p=0.752). There were no acute Grade 3 or 4 GI 
toxicities. Late Grade 3 GI toxicity, rectal bleeding, was 
noted in 2 patient in high risk group (7.4%) only in 3-DRT+CK 
group but bleeding was stopped with 3 times laser 
coagulation in one patients. There was acute Grade 3 urinary 
frequency in one patient (3.74%) of high risk group of 3-
DRT+CK group . There were no late grade 3 to 4 GU toxicity 
in both group.  
